Trial Profile

Placebo-Controlled, Double-Blind, Phase 2/3 Efficacy and Safety Trial of HLCM051 (MultiStem) in Patients With Ischemic Stroke

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 19 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Invimestrocel (Primary)
Indications Ischaemic stroke
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms TREASURE
Sponsors Healios

Most Recent Events

16 Jan 2024 Results reporting multiStem safety and efficacy findings from this trial in patients treated within 18 to 36 hours after ischemic stroke onset published in the JAMA Neurology
15 Jan 2024 Status changed from active, no longer recruiting to completed.
09 Jan 2023 According to Athersys media release, in November 2022 the company conducted a meeting of Key Opinion Leaders (KOL's) to discuss the potential changes to given clinical findings from this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com